Patents by Inventor James DeGregori

James DeGregori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of tyrosine kinase inhibitor in cancer treatment
    Patent number: 10076520
    Abstract: The present invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering a tyrosine kinase inhibitor to a cancer patient who is undergoing cancer treatment in order to reduce apoptosis of non-cancerous cells.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: September 18, 2018
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Mary E. Reyland, Sten Wie, James DeGregori
  • USE OF TYROSINE KINASE INHIBITOR IN CANCER TREATMENT
    Publication number: 20160228436
    Abstract: The present invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering a tyrosine kinase inhibitor to a cancer patient who is undergoing cancer treatment in order to reduce apoptosis of non-cancerous cells.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 11, 2016
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Mary E. Reyland, Sten Wie, James DeGregori
  • Adenoviral mediated gene transfer into lymphocytes
    Patent number: 6245966
    Abstract: The present application shows that the expression of Coxsackievirus and/or Adenovirus (CAR) in various lymphocyte cell lines is sufficient to facilitate the efficient transduction of these cells by adenoviruses. This property of CAR does not require its cytoplasmic domain. Use of a truncated CAR (tCAR) lacking the cytoplasmic domain has the unexpected advantage in that integrin expression is not increased in lymphocytes expressing tCAR, whereas lymphocytes expressing full-length CAR exhibit upregulated integrin expression. Further provided are transgenic mice which have been genetically engineered for tissue-specific (lymphocyte) expression of tCAR.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: June 12, 2001
    Assignee: University Technology Corporation
    Inventor: James DeGregori